KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Asset Writedowns and Impairment (2022 - 2025)

Amgen (AMGN) has 4 years of Asset Writedowns and Impairment data on record, last reported at $400.0 million in Q3 2025.

  • For Q3 2025, Asset Writedowns and Impairment rose 555.74% year-over-year to $400.0 million; the TTM value through Dec 2025 reached $1.2 billion, up 654.72%, while the annual FY2025 figure was $1.2 billion, 654.72% up from the prior year.
  • Asset Writedowns and Impairment reached $400.0 million in Q3 2025 per AMGN's latest filing, down from $800.0 million in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $851.0 million in Q4 2023 and bottomed at $2.0 million in Q4 2022.
  • Average Asset Writedowns and Impairment over 4 years is $277.1 million, with a median of $64.5 million recorded in 2024.
  • Peak YoY movement for Asset Writedowns and Impairment: surged 42450.0% in 2023, then tumbled 96.47% in 2024.
  • A 4-year view of Asset Writedowns and Impairment shows it stood at $2.0 million in 2022, then soared by 42450.0% to $851.0 million in 2023, then crashed by 96.47% to $30.0 million in 2024, then skyrocketed by 1233.33% to $400.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Asset Writedowns and Impairment were $400.0 million in Q3 2025, $800.0 million in Q1 2025, and $30.0 million in Q4 2024.